1,284
Views
7
CrossRef citations to date
0
Altmetric
Article

Synthesis and structure-activity relationships of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives as 5-lipoxygenase inhibitors

ORCID Icon, &
Pages 1471-1482 | Received 10 Apr 2020, Accepted 16 Jun 2020, Published online: 08 Jul 2020

References

  • Ferguson AD, McKeever BM, Xu S, et al. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 2007;317:510–2.
  • Radmark O, Werz O, Steinhilber D, et al. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 2007;32:332–41.
  • Hofmann B, Steinhilber D. 5-Lipoxygenase inhibitors: a review of recent patents (2010-2012). Expert Opin Ther Pat 2013;23:895–909.
  • Radmark O, Werz O, Steinhilber D, Samuelsson B. 5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease. Biochim Biophys Acta 2015;1851:331–9.
  • Montuschi P. Leukotrienes, antileukotrienes and asthma. Mini Rev Med Chem 2008;8:647–56.
  • Riccioni G, Back M. Leukotrienes as modifiers of preclinical atherosclerosis? The Sci World J 2012;2012:490968.
  • Steinhilber D, Hofmann B. Recent advances in the search for novel 5-lipoxygenase inhibitors. Basic Clin Pharmacol Toxicol 2014;114:70–7.
  • Sarveswaran S, Chakraborty D, Chitale D, et al. Inhibition of 5-lipoxygenase selectively triggers disruption of c-Myc signaling in prostate cancer cells. J Biol Chem 2015;290:4994–5006.
  • Pergola C, Werz O. 5-Lipoxygenase inhibitors: a review of recent developments and patents. Expert Opin Ther Pat 2010;20:355–75.
  • Boudreau LH, Lassalle-Claux G, Cormier M, et al. New hydroxycinnamic acid esters as novel 5-lipoxygenase inhibitors that affect leukotriene biosynthesis. Mediators Inflamm 2017;2017:6904634.
  • Boschi D, Giorgis M, Cena C, et al. Multitarget drugs: synthesis and preliminary pharmacological characterization of zileuton analogues endowed with dual 5-LO inhibitor and NO-dependent activities. ChemMedChem 2010;5:1444–9.
  • Stewart AO, Bhatia PA, Martin JG, et al. Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors. J Med Chem 1997;40:1955–68.
  • Corey EJ, Cashman JR, Kantner SS, Wright SW. Rationally designed, potent competitive inhibitors of leukotriene biosynthesis. J Am Chem Soc 1984;106:1503–4.
  • Summers JB, Gunn BP, Mazdiyasni H, et al. In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase. J Med Chem 1987;30:2121–6.
  • Summers JB, Gunn BP, Martin JG, et al. Structure-activity analysis of a class of orally active hydroxamic acid inhibitors of leukotriene biosynthesis. J Med Chem 1988;31:1960–4.
  • Reck F, Zhou F, Girardot M, et al. Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A. J Med Chem 2005;48:499–506.
  • Bolasco A, Carradori S, Fioravanti R. Focusing on new monoamine oxidase inhibitors. Expert Opin Ther Pat 2010;20:909–39.
  • Leach KL, Brickner SJ, Noe MC, Miller PF. Linezolid, the first oxazolidinone antibacterial agent. Ann N Y Acad Sci 2011;1222:49–54.
  • Pandit N, Singla RK, Shrivastava B. Current updates on oxazolidinone and its significance. Int J Med Chem 2012;2012:159285.
  • Phillips OA, Sharaf LH. Oxazolidinone antimicrobials: a patent review (2012-2015). Expert Opin Ther Pat 2016;26:591–605.
  • Kombian SB, Phillips OA. In vitro electrophysiological investigations of the acute effects of linezolid and novel oxazolidinones on central nervous system neurons. Neuroscience 2011;180:53–63.
  • Hedaya OM, Mathew PM, Mohamed FH, et al Antiproliferative activity of a series of 5-(1H-1,2,3-triazolyl) methyl- and 5-acetamidomethyl-oxazolidinone derivatives. Mol Med Rep 2016;13:3311–8.
  • Qaddoumi MG, Phillips OA, Kombian SB. A novel oxazolidinone derivative PH192 demonstrates anticonvulsant activity in vivo in rats and mice. Eur J Pharm Sci 2019;130:21–6.
  • Phillips OA, Udo EE, Ali AA, Al-Hassawi N. Synthesis and antibacterial activity of 5-substituted oxazolidinones. Bioorg Med Chem 2003;11:35–41.
  • Phillips OA, D’Silva R, Bahta TO, et al. Synthesis and biological evaluation of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives. Eur J Med Chem 2015;106:120–31.
  • Hanke T, Dehm F, Liening S, et al Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo. J Med Chem 2013;56:9031–44.
  • Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008;372:1073–87.
  • Davis BJ, Flanagan BF, Gilfillan AM, et al. Nitric oxide inhibits IgE-dependent cytokine production and Fos and Jun activation in mast cells. J Immunol 2004;173:6914–20.
  • Pufahl RA, Kasten TP, Hills R, et al. Development of a fluorescence-based enzyme assay of human 5-lipoxygenase. Anal Biochem 2007;364:204–12.